Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

65.69USD
1:19pm EDT
Price Change (% chg)

$1.34 (+2.08%)
Prev Close
$64.35
Open
$64.58
Day's High
$65.95
Day's Low
$64.41
Volume
339,789
Avg. Vol
974,572
52-wk High
$67.12
52-wk Low
$48.89

LLY.N

Chart for LLY.N

About

Eli Lilly and Company, discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products. The Company also has an animal health business segment. It manufactures and distributes its products through facilities in the United States, Puerto Rico, and 15 other countries. Its products are sold... (more)

Overall

Beta: 0.48
Market Cap (Mil.): $71,898.79
Shares Outstanding (Mil.): 1,117.31
Dividend: 0.49
Yield (%): 3.05

Financials

  LLY.N Industry Sector
P/E (TTM): 25.76 33.08 33.86
EPS (TTM): 2.50 -- --
ROI: -- 18.26 17.53
ROE: -- 18.93 18.34
Search Stocks

Lilly profit plunges as cheaper generics take toll

- Eli Lilly and Co said its quarterly earnings plunged 58 percent, hurt by special charges and generic competition for its Cymbalta depression drug, but it affirmed its full-year profit forecast.

23 Oct 2014

Stada secures third license for copycat biotech drug: CEO

BAD VILBEL Germany - Germany's Stada plans to bring a copy of Eli Lilly's Forteo osteoporosis treatment to market, its chief executive said, as the generic drugmaker moves further into the sale of cheaper alternatives for costly biotech drugs.

10 Oct 2014

EU mergers and takeovers (Oct 3)

BRUSSELS, Oct 3 - The following are mergers under review by the European Commission and a brief guide to the EU merger process:

03 Oct 2014

EU Commission clears Eli Lilly, Novartis deal

BRUSSELS - EU antitrust regulators approved U.S. drugmaker Eli Lilly's $5.4 billion takeover of Swiss peer Novartis's animal health business on Friday.

03 Oct 2014

EU Commission clears Eli Lilly-Novartis animal health deal

BRUSSELS, Oct 3 - EU antitrust regulators approved U.S. drugmaker Eli Lilly's $5.4 billion takeover of Swiss peer Novartis's animal health business on Friday.

03 Oct 2014

EU to extend Zimmer, Biomet probe, clear Eli Lilly, Novartis deal: sources

BRUSSELS - EU antitrust regulators will open an extensive probe into Zimmer's $13.4 billion bid for Biomet, concerned that the creation of the world's second-largest orthopedic products group may hurt competition, three people familiar with the matter said on Thursday.

02 Oct 2014

UPDATE 2-EU to extend Zimmer, Biomet probe, clear Eli Lilly, Novartis deal - sources

* Zimmer may have to offer concessions to allay EU worries

02 Oct 2014

Eli Lilly stops development of lupus drug; XTL shares soar

- Eli Lilly and Co said it would stop the development of its drug to treat the autoimmune disorder lupus, after it was found to be not effective enough in late-stage trials.

02 Oct 2014

EU to extend Zimmer, Biomet probe, clear Eli Lilly, Novartis deal - sources

BRUSSELS, Oct 2 - EU antitrust regulators will widen a probe into Zimmer Holdings Inc's $13.4 billion bid for Biomet Inc but clear Eli Lilly's offer for a Novartis AG unit, three people familiar with the matter said on Thursday.

02 Oct 2014

Eli Lilly to drop development of lupus drug

Oct 2 - Eli Lilly and Co said it would discontinue the development of its lupus drug as the treatment was not found to be effective enough in two late-stage trials.

02 Oct 2014

Competitors

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks